54 results about "Primary lesion" patented technology

The invention provides systems, methods and a node accessing and anchoring device, comprising an elongated shaft, a tissue cutting member, at least one anchoring element extending from a position at or near the distal end of the shaft; and a radiation detector. The radiation detector is effective to locate and identify sentinel lymph nodes following injection of radioactive material into a primary lesion site within a patient. The tissue cutting member, which may be activated with radio frequency energy, is effective to allow access of the elongated shaft to a sentinel lymph node. The anchoring elements are effective to anchor the device to or adjacent a sentinel lymph node accessed by the device. Anchoring elements may assume radially, longitudinally, or mixed radially and longitudinally curved or coiled configurations when deployed.

The use of a composition containing at least one not easily water-soluble calcium salt and / or the composite material thereof, to protect and / or therapeutically treat and / or preventively treat teeth and / or bones in case of damage or prevent damage resulting from external influences, especially biological, chemical, physical, and / or microbiological influences, particularly to prevent and repair bone and tooth erosion, especially the enamel, maintain the enamel, protect teeth from aggressive acids, particularly caused by bacterial activity or the effect of acids contained in food, protect teeth from demineralizing, seal cracks, provide protection against and / or repair primary lesions and / or initial cavities in the enamel, smooth the tooth surface, prevent cavities make it easier to clean teeth, improve the mechanical resistance of teeth, and generally keep teeth healthy.

The present invention relates to a balloon dilation catheter carried with medicine. The invention provided balloon dilation catheter includes a balloon and multiple medicine coated on the balloon, and one of the medicine is probucol. The probucol can not only improve medicine absorptivity of cells in blood vessel greatly, but also can reduce loss of other medicine in blood transportation process at the same time. Comparing with the prior balloon dilation catheter, the invention provided balloon dilation catheter carried with medicine has better impact in preventing and curing restenosis, especially suitable for curing restenosis lesion in vascular stent of coronary artery, carotid artery, renal artery etc, or instead the prior stent to cure primary lesions clinically of slight stenosis, fewer stenosis artery.

The invention provides systems, methods and a node accessing and anchoring device, comprising an elongated shaft, a tissue cutting member, at least one anchoring element extending from a position at or near the distal end of the shaft; and a radiation detector. The radiation detector is effective to locate and identify sentinel lymph nodes following injection of radioactive material into a primary lesion site within a patient. The tissue cutting member, which may be activated with radio frequency energy, is effective to allow access of the elongated shaft to a sentinel lymph node. The anchoring elements are effective to anchor the device to or adjacent a sentinel lymph node accessed by the device. Anchoring elements may assume radially, longitudinally, or mixed radially and longitudinally curved or coiled configurations when deployed.

The invention discloses a nasopharyngeal carcinoma primary lesion clinical target area automatic drawing method based on a mutual correlation rule. The method comprises a step of generating a binary image of a nasopharyngeal primary tumor area, a step of removing instable data of a tumor outermost layer, a step of carrying out data discretization operation on the image sequence of a template CT, and dividing the image sequence and generating corresponding three-dimensional grids, a step of counting the frequency that voxel combination appears, and establishing a database of a correlation rule, a step of reading new patient gross tumor data with the need of drawing a clinical target area, using the mutual correlation rule, simulating tumor growth, and automatically drawing a clinical radiotherapy target area. Compared with manual drawing at present, the automation of drawing is realized by the system, and the working efficiency of a doctor is improved. A drawing result reaches a drawing standard required by the doctor, and local adjustment is taken as post processing and is provided for the doctor for selection.

The invention provides an external ointment for treating skin diseases as well as a preparation method and application thereof, and relates to the technical field of traditional Chinese medicines. The external ointment for treating skin diseases is prepared through reasonable matching of raw material medicines such as coptis chinensis, angelica sinensis, golden cypress, rehmannia glutinosa, zedoary, lithospermum, pomegranate barks and bletilla striata, the prepared external ointment has the effects of clearing heat and cooling blood, drying dampness and removing toxin, killing insects and relieving etching, preventing bacteria and diminishing inflammation as well as promoting skin ulcer and eczema exudation treatment, drug dependence or toxic and / or side effects can be prevented, and the problems that a conventional adenosine hormone ointment can easily have drug dependence, dermatitis can easily reoccur after the ointment is not used and has the trend of exacerbation, and the diseases can be relatively hard to treat as ultimately primary lesion is not treated and corticosteroid-dependent dermatitis is secondarily resulted, can be solved. The external ointment disclosed by the invention can be widely applied to diseases such as skin redness, swelling and itching, skin ulcer and eczema caused by various reasons.

The invention discloses a prediction method and system for latent N2 lymph node metastasis of surrounding NSCLC, and the method comprises the steps: collecting the imaging omics features and clinicalpathological features of a primary lesion in a clinical staging N1 stage and a pulmonary portal lymph node at the same side in PET-CT; establishing a Nomogram model by utilizing the imaging omics characteristics and the clinical pathological characteristics; scoring a patient in clinic based on the Nomogram model to obtain a corresponding risk probability coefficient; and utilizing the risk probability coefficient to predict and evaluate the probability of occurrence and transfer of the latent N2 lymph node. According to the invention, the image omics features are extracted through the convolutional neural network, so the accuracy and reliability of the classification or prediction of the imaging omics are further improved; the Nomogram based on the imaging omics can provide personalized information about whether lymph node metastasis exists or not according to the actual situation of each non-small cell lung cancer patient more visually and more accurately, so the unnecessary medicalexamination and operation of the patient are avoided.

The present invention belongs to the technical fields of biomedical medicine and nano-medicine, and relates to a stem cell tumor targeting system with internal nano prodrug and a preparation method thereof. The method uses stem cells as cell carriers to prepare an anti-tumor targeting system with general formula of Stem cells-(RGD-PPCD)n through endocytosis and inner load of nano prodrug. The nano prodrug has the characteristics of targeting, sustained release and acid sensitivity release; and the stem cell carrier can remotely target primary lesion and metastasis of tumor. In vitro experimental results show that the stem cells after drug load can retain the proliferation capacity and tumor migration characteristics; and the constructed system is stable to ensure that the drug stays in the form of nano-prodrug for several days in the cells, and can slowly release the drug. In vivo experimental results show that the constructed stem cell targeting system can significantly prolong the survival time of tumor-bearing animals and can maintain normal neurobehavioral characteristics of tumor-bearing animals in comparison with the original drug and nano prodrugs, so as to play the efficient, secure and long-lasting anti-tumor effect.

The embodiment of the invention provides a tumor clinical target area automatic sketching method and system based on a conditional random vector field, and the method comprises the following steps: S1, carrying out data discrete operation of an image sequence of a template CT, and generating a binary image of a tumor primary lesion region; s2, preprocessing a read primary lesion tumor data, defining a transfer characteristic function and a state characteristic function in a given data set, training a model, and determining parameters; and S3, reading primary tumor data of a new patient to obtain a corresponding binary image, and continuously iteratively calculating the state transition probability between adjacent voxels from the general tumor target region to the outside according to a set voxel state transition formula, thereby finally obtaining the global tumor probability invasion probability. According to the method, the conditional random vector field is used, the invasion probability of the tumor can be predicted, the radiotherapy clinical target area is automatically determined, and a prediction result is more reasonable and more suitable for the actual clinical situation.

The invention discloses traditional Chinese medicine decoction for treating stomach cancer, belonging to the field of traditional Chinese medicines. The traditional Chinese medicine decoction for treating stomach cancer is prepared from the following bulk drugs by weight: 10 g of frankincense, 10 g of cinnamon, 15 g of selfheal, 15 g of agilawood, 15 g of radix ophiopogonis, 15 g of curcuma zedoary, 15 g of myrrh, 15 g of astragalus membranaceus, 15 g of the root of red-rooted salvia, 15 g of glossy privet fruit, 15 g of schisandra chinensis, 15 g of Chinese angelica, 15 g of root of common peony, 15 g of the rhizome of chuanxiong, 10 g of corydalis tuber, 10 g of rehmannia, 10 g of lucid ganoderma, 10 g of oldenlandia diffusa, 10 g of radix polygonati officinalis, 10 g of moutan bark, 10 g of edible tulip, 10 g of immature bitter orange, 10 g of lithospermum, and 5 g of musk. The traditional Chinese medicine decoction for treating stomach cancer has the effects of supporting body resistance, reinforcing qi, nourishing blood, promoting circulation, removing stasis, clearing heat and removing toxicity and is capable of effectively controlling metastasis of primary lesion and continuous diffusion of metastatic lesion and obviously relieving stomach cancer clinical symptoms; the traditional Chinese medicine decoction for treating stomach cancer has obvious curative effect on treatment of stomach cancer.

The invention provides a human colon carcinoma cell line DXH-1, which is derived from primary lesion of human sigmoid colon carcinoma, and application of the human colon carcinoma cell line as a human colon carcinoma occurrence, human colon carcinoma development or human colon carcinoma transfer cell model, application of the human colon carcinoma cell line in establishing a human colon carcinoma animal model and application of the human colon carcinoma cell line in researching a human colon carcinoma occurrence mechanism and / or medicines for treating the human colon carcinoma. The human colon carcinoma cell line DXH-1 disclosed by the invention can be stably transferred for more than 50 generations, so that an appropriate material is provided for colorectal carcinoma mechanism and drug screening. In an in-vivo nude mice experiment, the human colon carcinoma cell line shows a relatively strong tumorigenesis cavity, and the cell line, transplanted subcutaneously in nude mice by 1*106 cells, is capable of promoting 100% (5 / 5) tumorigenesis after 35 days; the DXH-1 cell has certain drug resistance to colon carcinoma chemotherapeutics (5FU, such as oxaliplatin, irinotecan and the like), so that a material is provided to the researches on a colon carcinoma chemotherapeutic resistance mechanism; and the human colon carcinoma cell line DXH-1 is preserved in China Center for Type Culture Collection in Wuhan University, Wuhan, China with number of CCTCC No: C201543.

The invention provides Chinese medicinal formulae for treating cerebral apoplexy and a method of application thereof. Based on the degrees and clinical manifestations of cerebral apoplexy, the Chinese medicinal formulae are applied externally on head respectively by suiting the medicine to the illness, specifically, a Huoxue musk liquid is adopted for patients with meridian cerebral ischemia, a Tianma gouteng drink is adopted for patients with meridian multiple cerebral infarction accompanied with acroparalysis, a Tianma zhibao liquid is adopted for patients with Zang-Fu blockage syndrome, a Renshen huiyang liquid is adopted for patients with Zang-Fu prostration syndrome, or a Xionghuang zhitan powder is simultaneously adopted for external application on foot bottom. The Chinese medicinal formulae are applied for 24 hours and changed once per day, and one course of treatment lasts for 7 days. With the Chinese medicinal formulae for treating cerebral apoplexy, head treatment and foot bottom treatment are combined, primary lesion can be treated at the early stage of occurrence of disease and the sequela of acroparalysis is treated with quick effect without any toxic side effects. Shown by statistical results, the treatment group has an obvious effect on reducing the disability rate and death rate of patients, the effective rate is 91%, and the obvious effective rate is 62%. The Chinese medicinal formulae for treating cerebral apoplexy also have notable curative effects on nerve headache, refractory insomnia, neurosis and the like.

The invention relates to the field of medical treatment, in particular to a storing and recording method and classified collecting box for organ specimens and lymph node specimens in surgical operations. The classified collecting box for the organ specimens and the lymph node specimens in the surgical operations comprises a classification box I and a classification box II. The upper surface of the classification box I is divided into a primary lesion storing area and a distant metastasis storing area. An organ specimen storing tank is arranged in the primary lesion storing area. An anatomical atlas is arranged on the upper surface of the classification box II, and a plurality of lymph node specimen storing tanks are formed in the upper surface of the classification box II. The storing and recording method for the organ specimens and the lymph node specimens in the surgical operations comprises the steps that the classified collecting box for the organ specimens and the lymph node specimens in the surgical operations is adopted; and taken-down distant metastasis tissue is placed into distant metastasis storing tanks, then corresponding marks are pasted to the positions near the distant metastasis storing tanks, and the specific sampling positions of the distant metastasis tissue in corresponding sampling organs are marked on mark pasters. Comprehensive and detailed recording can be carried out on related information of the specimens in the surgical operations.

The invention discloses a method for automatically delineating clinical target areas of primary lesions of nasopharyngeal carcinoma based on GrowCut. The method includes the following steps: performing discrete operations on image sequences of template CT to generate corresponding three-dimensional grids; In the area, count the frequency of joint occurrences of spatially continuous grid points in the training set, obtain the corresponding correlation rules, and store them in the database; read the primary tumor data of nasopharyngeal carcinoma from new patients, and regard the primary tumor area as Seed points, set thresholds and termination conditions, innovatively use GrowCut, an algorithm originally applied to image segmentation, to simulate tumor growth, and realize automatic delineation of radiotherapy target areas. The invention can assist in the formulation of clinical radiotherapy plans, realize the automatic delineation of clinical radiotherapy target areas, meet the delineation standards for clinical applications, and improve the work efficiency of doctors. In addition, local adjustments will be used as post-processing for doctors to choose.

The invention relates to a medical information processing method. The method comprises the steps: obtaining first to third recognition information based on the AI recognition of first medical information, second medical information and third medical information, wherein the first recognition information comprises the tumor primary lesion condition, the second recognition information comprises theregional lymph node fatigue condition, and the third identification information comprises a remote transfer condition; and outputting interpretation information according to the first recognition information, the second recognition information, the third recognition information and standard information. The medical information processing system is linked to a medical diagnosis business data systemthrough a corresponding data interface, and comprises: an AI identification module configured to obtain identification information including different pathological information based on different medical information, and an analysis module used for obtaining the interpretation information according to the different identification information and the standard information. Through the embodiments ofthe invention, intelligent inference of corresponding diagnosis information can be realized, the working efficiency of doctors is improved, and the clinical data preparation cost is reduced.

The invention discloses traditional Chinese medicine composition for treating oral cancer, esophageal cancer, nasopharyngeal carcinoma and gastric cancer and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition is prepared from the raw materials in parts by weight as follows: 1-3 parts of spreading hedyotis herbs, 1-3 parts of barbated skullcup herbs, 1-3 parts of Chinese lobelia herbs, 1-3 parts of Yunnan manyleaf paris rhizomes, 3-5 parts of milkvetch roots, 0.5-1.5 parts of frankincense, 0.5-1.5 parts of myrrh, 1-3 parts of licorice roots, 1-3 parts of honeysuckle flowers, 3-5 parts of snakegourd roots and 0.5-1.5 parts of ganoderma lucidum spore powder. The invention further discloses a preparation method of the traditional Chinese medicine composition as well as a medicine for treating the oral cancer, the esophageal cancer, the nasopharyngeal carcinoma and the gastric cancer. The traditional Chinese medicine composition can effectively control metastasis of primary lesions and continuous diffusion of the metastatic lesions and remarkably alleviate clinical symptoms of the oral cancer, the esophageal cancer, the nasopharyngeal carcinoma and the gastric cancer; the composition has no toxic or side effects, is definite in curative effect, takes effect quickly and is safe to use and convenient to take.

The embodiment of the invention provides a GrowCut-based nasopharyngeal carcinoma primary lesion clinical target region automatic sketching method and system. The method comprises the following steps:S1, carrying out data discrete operation on an image sequence of a template CT, gridding a three-dimensional CT image to obtain a corresponding three-dimensional grid, reading a tumor contour file drawn by a doctor in a training set, and generating a binary image of a tumor primary lesion area; S2, performing preprocessing operation on the read primary lesion tumor data by adopting opening operation, mining a cross-correlation relationship between adjacent tumors, counting the frequency of joint occurrence of adjacent voxels, storing a statistical result, and establishing a database of cross-correlation rules; S3, reading the primary tumor data of a new patient, and continuously updating the intensity value of each discrete grid point; and giving different loss cost thresholds to obtain corresponding clinical radiotherapy target area ranges. The drawing habit of a doctor is learned, the clinical radiotherapy target area drawing rule is obtained, the drawing time of the doctor is saved, and the result is more reliable.

The invention discloses traditional Chinese medicine composition for treating prostatic cancer and intestinal cancer, a preparation method and a medicine comprising the traditional Chinese medicine composition, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition is prepared from the raw materials in parts by weight as follows: 1-3 parts of barbated skullcup herbs, 1-3 parts of giant knotweed rhizomes, 1-3 parts of solidago, 0.5-1.5 parts of coptis chinensis, 1-3 parts of broomjutre sida herbs, 1-3 parts of viscid germander herbs, 1-3 parts of laciniate kalanchoe herbs and 0.05-0.15 parts of musk. The invention further discloses a preparation method of the traditional Chinese medicine composition and a medicine comprising the traditional Chinese medicine composition. The traditional Chinese medicine composition can effectively control metastasis of primary lesions and continuous diffusion of the metastatic lesions and remarkably alleviate clinical symptoms of the prostatic cancer and the intestinal cancer; the composition has no toxic or side effects, can remarkably alleviate pain of a patient, is definite in curative effect, takes effect quickly and is safe to use, controllable in quality and convenient to take.

The invention discloses a prediction method, a prediction model training method and a related device. The prediction model training method comprises the steps of obtaining an initial training sample from a tumor genome map database, and obtaining an initial test sample from a clinical database; performing batch effect elimination processing on the initial training sample and the initial test sample to obtain a final training sample and a final test sample; performing classification training on the final training sample to obtain a prediction model of the tumor primary lesion; and performing performance verification on the prediction model of the tumor primary lesion obtained through classification training by using the final test sample, and obtaining the trained prediction model of the tumor primary lesion based on a performance verification result. According to the scheme, the type of the tumor primary lesion can be predicted.

The invention discloses a gene detection kit for detecting a chromophobe cell carcinoma subtype in renal carcinoma. The gene detection kit comprises a primer for detecting complete methylation at 74bp-165bp sites of a gene ENST00000571911. The 74bp-165bp sites of the gene ENST00000571911 are completely methylated in a primary lesion of the chromophobe cell carcinoma, while paracancerous normal tissue of the chromophobe cell carcinoma and primary lesions and paracancerous normal tissue of the other three subtypes are all unmethylated, so that the chromophobe cell carcinoma subtype can be diagnosed by detecting whether the 74bp-165bp sites of the gene ENST00000571911 are completely methylated; the specificity is strong; the diagnostic accuracy rate of 45 samples in the experiment is 100%.

Primary and metastatic lesions are distinguished in the treatment plan. A radiotherapy system according to an embodiment includes processing circuitry. The processing circuitry specifies at least onetumor area in a medical image of a patient, and outputs classification result information including a result of classifying this / these tumor area(s) as either a primary lesion or a metastatic lesion based on an image feature amount of this / these tumor area (s).

Ointment for treating blister type beriberi and a preparing method thereof are disclosed. The blister type beriberi usually is beriberi in an acute developing period, begins abruptly, and is serious in summer and mild in winter. Primary lesions mainly comprise phlyctenules. The phlyctenules are in groups or sporadic, thick in wall and clear in blister fluid and are commonly seen between toes, on the sole heart and on foot side border. The phlyctenules are below the epidermal stratum corneum. As the stratum corneumin of vola pedis parts is thick, the phlyctenule wall is not liable to perforate and surrounding skin is free of flush. The ointment is prepared from following raw materials by weight: 3-5 parts of Chinese dittany bark, 6-8 parts of lysimachia christinae hance, 6-8 parts of origanum vulgare, 8-10 parts of myrrh, 8-10 parts of sargentgloryvine stem, 4-6 parts of chastetree fruit, 4-6 parts of atractylodes macrocephala, 3-5 parts of erycibe obtusifolia, 10-12 parts of chitosan, 70-80 parts of vaseline and 40-50 parts of glycerol. Medicine effects of components are synergistic. The ointment has obvious treating effects for the blister type beriberi.

Central pain syndrome (CPS) is a debilitating condition that affects a large number of patients with a primary lesion or dysfunction in the central nervous system. Despite its discovery over a century ago, the pathophysiology underlying the development and maintenance of CPS is poorly understood. The present invention is drawn to novel methods of treating CPS. In certain aspects, the invention is drawn to the novel discovery of the role of the zona incerta (ZI) in CPS and methods of exploiting this novel discovery for the treatment of CPS.

The invention discloses application of an STC2 gene as a colorectal cancer liver metastasis molecular marker. The invention provides a kit for identifying or assisting in identifying whether a to-be-detected colorectal cancer patient has liver metastasis or not. The kit comprises a reagent for detecting expression quantity of the STC2 gene and a carrier for recording the following judgment standards: if the expression quantity of the STC2 gene in a cancer tissue of the to-be-detected colorectal cancer patient is higher than that of the STC2 gene in the cancer tissue of the diagnosed non-liver metastasis colorectal cancer liver patient, and the two have remarkable difference, the to-be-detected colorectal cancer patient has or is candidate to have liver metastasis. Experiments in the invention prove that expression of the STC2 in primary lesion of patients in the colorectal cancer liver metastasis group is remarkably higher than that in a non-liver metastasis group, and in-vitro functional experiment result at a later period indicates that STC2 possibly promotes tumor metastasis invasion ability to participate in a colorectal cancer liver metastasis process, so that clue is provided for further finding the colorectal cancer liver metastasis molecular marker.

The invention discloses a biomarker or a biodegradation product thereof for epilepsy prediction, diagnosis, treatment and prognosis evaluation. The protein is named as Hemoglobin subunit beta, and theencoding gene of the biomarker is HBB. Particularly, the invention relates to a proteomic screening and detection method for a Hemoglobin subunit beta protein or a biodegradation product thereof. Results of the method show that before and after epilepsy primary lesion resection operation of a patient suffering from epilepsy, the contents of Hemoglobin subunit beta or biodegradation products thereof in serum are remarkably different (as shown in the figure 1 accompanying the abstract). The biomarker protein Hemoglobin subunit beta or the biodegradation product thereof disclosed by the invention has great significances in fields such as epilepsy research, prediction, diagnosis, treatment and prognosis evaluation.

The invention discloses application of an STC2 gene as a colorectal cancer liver metastasis molecular marker. The invention provides a kit for identifying or assisting in identifying whether a to-be-detected colorectal cancer patient has liver metastasis or not. The kit comprises a reagent for detecting expression quantity of the STC2 gene and a carrier for recording the following judgment standards: if the expression quantity of the STC2 gene in a cancer tissue of the to-be-detected colorectal cancer patient is higher than that of the STC2 gene in the cancer tissue of the diagnosed non-liver metastasis colorectal cancer liver patient, and the two have remarkable difference, the to-be-detected colorectal cancer patient has or is candidate to have liver metastasis. Experiments in the invention prove that expression of the STC2 in primary lesion of patients in the colorectal cancer liver metastasis group is remarkably higher than that in a non-liver metastasis group, and in-vitro functional experiment result at a later period indicates that STC2 possibly promotes tumor metastasis invasion ability to participate in a colorectal cancer liver metastasis process, so that clue is provided for further finding the colorectal cancer liver metastasis molecular marker.

The invention belongs to the technical field of the traditional Chinese medicine and especially relates to a traditional Chinese medicine compound for treating esophagus cancer and a preparation method thereof. The traditional Chinese medicine compound is prepared from the following raw materials in parts by weight: 25-35 parts of peperomia blanda, 20-25 parts of rabdosia rubescens, 15-20 parts ofoldenlandia diffusa, 10-15 parts of inula flower, 10-15 parts of myrrh, 15-25 parts of subprostrate sophora, 8-15 parts of liquorice, 15-25 parts of ginseng, 8-13 parts of mastic and 25-35 parts of sculellaria barbata. The traditional Chinese medicine compound provided by the invention is capable of effectively controlling the transferring of primary lesion and the spreading of metastatic lesion,is capable of obviously relieving the clinical symptoms of esophagus cancer, is free from toxic or side effect, is capable of obviously relieving the pain of the patient and is characterized by accuracy in curative effect, quickness in taking effect, use safety, controllable quality and convenience in taking.

The invention belongs to the technical field of molecular biomedicine, and particularly relates to a high-mobility protein HMGB3 and a gene thereof as molecular markers for screening and diagnosing early stage of cervical lesion and application of the molecular markers. According to the molecular markers and the application thereof, the differential genes in each progress stage of the cervical lesion are screened out from a GEO database, then statistics is carried out according to the expression conditions of the differential genes in the lesion tissue, so that the gene HMGB3 with higher priority is screened out for subsequent verification. Verification experiments prove that the expression positive rate of HMGB3 is far higher than the positive rate of an existing diagnosis method in the cervical epithelium CIN1 level, namely cervical primary lesion, it is indicated that the sensitivity of HMGB3 serving as the marker has obvious advantages compared with the existing diagnosis method, and HMGB3 can be used for early detection, screening and diagnosis of cervical lesion.

I study Neijing and Compendium of Materia Medica for many years, screen out natural medicinal materials which grow in China, and develop a special-acting drug-a traditional Chinese medicine anticanceragent which can resist malignant tumors in the middle and advanced stages. The agent is non-toxic, and has special effects on lung, stomach, liver, kidney, heart disease, esophagus, breast, thyroid,cervix, colorectal, leukemia and the like, and cure rate is much higher than 62%. For the human immunodeficiency virus, the agent can reduce a HIV viral load. The mechanism of the agent is to block anenergy source of cancer cells, resist the growth of tumor angiogenesis, enhance immune functions, (devour and destroy heterogeneity in blood), induce tumor cell apoptosis and block oncogene mutationand transcription. If the traditional Chinese medicine anticancer agent is taken, pain, nausea and vomiting are soon alleviated and disappeared. Diet is increased, sleep is improved, physical strengthis increased, and the development of the cancer cells is obviously controlled. A tumor block is softened, shrunk and disappeared. After two to three courses of treatment (three months after one course of the treatment), B-ultrasound or CT are used for re-examination of a patent with fast curative effect, a primary lesion disappears, no metastasis and recurrence occurs, and the patient has good health.

It is an object of the present invention to provide a medicament or a pharmaceutical composition, which is effective for the treatment of various cancers.More specifically, the present invention relates to a pharmaceutical composition for use in the treatment of cancers, which comprises rMV-SLAM-blind or rMV-V(−)-SLAM-blind. The pharmaceutical composition has the effect of causing the regression of tumor, even if it is intravenously administered, and it also exhibits effects on cancer metastasized from a primary lesion.